ArticleDiscover oncology2026
COG8 serves as a predictive and prognostic biomarker in lung adenocarcinoma and other human malignancies.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveThe main objective of this study is to investigate the dysregulated expression, clinical relevance, and underlying mechanisms of COG8 in lung adenocarcinoma (LUAD) and other human malignancies.
methodsWe assembled multi-cohort microarray and RNA sequencing data for tumor and non-tumor controls from global repositories including ArrayExpress, Gene Expression Omnibus, The Cancer Genome Atlas, and Genotype-Tissue Expression. COG8 protein expression in LUAD was evaluated using immunohistochemical staining. Differential expression was assessed using standardized mean difference (SMD) for pooled effects and Wilcoxon rank-sum tests for individual datasets. Clinical relevance of COG8 was examined using receiver operating characteristic analyses and Cox/Kaplan-Meier survival analyses. Correlation between COG8 expression and tumor mutation burden, microsatellite instability, neoantigen count, and TIMER scores was evaluated using Spearman's rank correlation. Gene set enrichment analysis was conducted to explore the potential signaling pathways associated with COG8 across tumor types.
resultsCOG8 mRNA was higher in LUAD compared to the control group (SMD = 0.29, 95% CI: 0.12-0.46, p < 0.05), consistent with COG8 protein levels by immunohistochemistry (p < 0.05). Elevated mRNA expression was associated with longer overall survival in LUAD (p < 0.05) and showed moderate discrimination between LUAD and controls (AUC = 0.72). COG8 mRNA was also overexpressed in 11 additional cancer types (p < 0.05). Higher COG8 expression was linked to worse prognosis in seven cancers (HR > 1; p < 0.05) and to improved overall and/or disease-specific survival in four cancers (HR < 1; p < 0.05). In certain cancers, COG8 expression correlated with tumor mutation burden, microsatellite instability, neoantigen count, and immune infiltration levels (p < 0.05). COG8 may impact signaling pathways such as cytokine-cytokine receptor interaction.
conclusionCOG8 exhibits aberrant expression in LUAD and eleven other human malignancies, holding clinical significance as a predictive and prognostic biomarker.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.